Repligen Corp
RGEN119.770USD
-1.560-1.29%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.73BCap. mercado
PérdidaP/E TTM
Más Datos de Repligen Corp Compañía
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Información de la empresa
Símbolo de cotizaciónRGEN
Nombre de la empresaRepligen Corp
Fecha de salida a bolsaApr 29, 1986
Fundada en1981
Director ejecutivoMr. Olivier Loeillot
Número de empleados1778
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 29
DirecciónBuilding 1, Suite 100
CiudadWALTHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02453
Teléfono17814499560
Sitio Webhttps://www.repligen.com/
Símbolo de cotizaciónRGEN
Fecha de salida a bolsaApr 29, 1986
Fundada en1981
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.82K
-47.79%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.82K
-47.79%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
North America
84.59M
50.00%
Europe
59.21M
35.00%
APAC/Other
25.38M
15.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 18 de may
Actualizado: dom., 18 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
13.38%
The Vanguard Group, Inc.
9.02%
BlackRock Institutional Trust Company, N.A.
8.70%
Roy T. Eddleman UEO
5.89%
State Street Global Advisors (US)
3.01%
Other
60.00%
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
13.38%
The Vanguard Group, Inc.
9.02%
BlackRock Institutional Trust Company, N.A.
8.70%
Roy T. Eddleman UEO
5.89%
State Street Global Advisors (US)
3.01%
Other
60.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
53.24%
Investment Advisor/Hedge Fund
36.52%
Hedge Fund
9.08%
Individual Investor
6.40%
Pension Fund
2.44%
Research Firm
1.88%
Bank and Trust
0.70%
Family Office
0.52%
Family Office
0.50%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1017
62.55M
111.32%
-2.87M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
2023Q1
1061
58.23M
104.67%
+1.01M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Associates, Inc.
7.52M
13.38%
+427.74K
+6.03%
Mar 31, 2025
The Vanguard Group, Inc.
5.07M
9.02%
-21.20K
-0.42%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
8.7%
+13.96K
+0.29%
Mar 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
State Street Global Advisors (US)
1.69M
3.01%
-2.27K
-0.13%
Mar 31, 2025
Invesco Advisers, Inc.
1.60M
2.84%
+768.85K
+93.02%
Mar 31, 2025
Champlain Investment Partners, LLC
1.46M
2.61%
-79.53K
-5.15%
Mar 31, 2025
Citadel Advisors LLC
1.33M
2.37%
+150.23K
+12.74%
Mar 31, 2025
Sands Capital Management, LLC
1.29M
2.3%
-70.06K
-5.14%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.22M
2.17%
-37.63K
-2.99%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Alger Mid Cap 40 ETF
4.53%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
BNY Mellon Innovators ETF
2.82%
iShares Health Innovation Active ETF
1.58%
Congress SMid Growth ETF
1.36%
VanEck Biotech ETF
1.33%
Franklin Genomic Advancements ETF
1.27%
WisdomTree BioRevolution Fund
0.97%
Pacer US Export Leaders ETF
0.77%
iShares Biotechnology ETF
0.66%
Ver más
Alger Mid Cap 40 ETF
Proporción4.53%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.02%
BNY Mellon Innovators ETF
Proporción2.82%
iShares Health Innovation Active ETF
Proporción1.58%
Congress SMid Growth ETF
Proporción1.36%
VanEck Biotech ETF
Proporción1.33%
Franklin Genomic Advancements ETF
Proporción1.27%
WisdomTree BioRevolution Fund
Proporción0.97%
Pacer US Export Leaders ETF
Proporción0.77%
iShares Biotechnology ETF
Proporción0.66%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
